Royalty Pharma officer proposes $1.72M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) officer Terrance Coyne reported a proposed sale of 34,791 common shares, with an aggregate market value of $1,723,546.14 and an approximate sale date of April 28, 2026. The shares are allocated as 32,916 by TPC RP 2021 LLC and 1,875 by TPC RP EPA1 LLC. The notice states that the sales are made in connection with a selling plan dated August 8, 2025, intended to comply with Rule 10b5-1(c).
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
selling plan financial
Performance Awards financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was the proposed RPRX sale connected to a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.